08.12.2011Mucopolysaccharidosis International ConferenceYou are hereEventsLife science events Mucopolysaccharidosis International Conference
Themes to be covered during the meeting with respective speakers:
1. Substrate Reduction Therapy
Zaccharon Pharmaceuticals Inc. (USA), MPS I, II, III
2. Chemical Chaperone Therapy
Prof. Mathieu Sollogoub, Paris, (France) MPS III B
Prof. Tanja Wrodnigg, Graz, (Austria), Morquio B/ Gaucher
Prof. Martin Olivier, Orléans, (France) MPS IVB, MPS VII
Prof. Alexey Pshezhetsky Montreal, (Canada) MPSIII C
3. Enzyme Replacement Therapy
Dr. Patrick Haslett, Shire Pharmaceuticals (UK) (Keynote)
Dr. Maurizio Scarpa, Padova, (Italy)
4. Genetic Therapy/Bone Marrow Transplantation
Prof. Marc Tardieu, Paris (France) (Keynote)
Prof. Jean-Michel Heard, Paris (France), MPS III B, Hurler
Prof. John Hopwood, Adélaide (Australia) (Keynote)
Dr. Dao Pan, Cincinnati (USA)
5. Alternative approaches for treating MPS
Prof. Lena Kjellén, Uppsala, (Sweden) (Keynote)
Prof. Marco Sardiello, Texas (USA) and Naples (Italy).
Prof G. Wegrzyn, Gdansk, (Poland).
Prof. Brian Bigger, Manchester, (UK)
Prof. Thomas Jensen , Orphazyme (NL)
6. The forgotten MPS: Sly, Morquio, Maroteaux -Lamy syndrome
Prof. Tanja Wrodnigg, Graz (Austria), Morquio B
Prof. Maurizio Scarpa, Padova, (Italy) Maroteaux-Lamy
7. Clinical care/Case studies
8. Family Experiences
Le Challenge Debiopharm InartisLa qualité de vie du patient en cours de traitement "Qui pourra changer le monde dans lequel nous vivons?”
Alcimed SàrlProfessional Services & Consulting, Business Development Services
Professional Services & Consulting, Communication / PR / Market research / Events
Professional Services & Consulting, Other
Alcimed is a consultancy located in Lausanne which can help you
in your market research, customer discovery and validation,
writing your business plan, and get you investor-ready!
. A positioning in innovation and new business consulting.
. A dual culture in technology and business.
. An ability to decipher new technologies and emerging trends.
. A fact-based approach with flexible methodologies.
. A business agility and proximity recognized by our clients.